Literature DB >> 28431104

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

Eoghan M McCarthy1, Emily Sutton2, Stephanie Nesbit2, Ben Parker1,3, David Jayne4, Bridget Griffiths5, David A Isenberg6, Anisur Rahman6, Caroline Gordon7,8, David P D'Cruz9, Benjamin Rhodes10, Peter Lanyon11, Edward M Vital12,13, Chee-Seng Yee14, Christopher J Edwards15,16, Lee-Suan Teh17, Mohammed Akil18, Neil J McHugh19,20, Asad Zoma21, Ian N Bruce1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28431104      PMCID： PMC5850864          DOI： 10.1093/rheumatology/kex044

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors:  Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2011-12

2.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

3.  Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

Authors:  M A Dooley; F Houssiau; C Aranow; D P D'Cruz; A Askanase; D A Roth; Z J Zhong; S Cooper; W W Freimuth; E M Ginzler
Journal:  Lupus       Date:  2013-01       Impact factor: 2.911

4.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Authors:  Ronald F van Vollenhoven; Michelle A Petri; Ricard Cervera; David A Roth; Beulah N Ji; Christi S Kleoudis; Z John Zhong; William Freimuth
Journal:  Ann Rheum Dis       Date:  2012-02-15       Impact factor: 19.103

5.  Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.

Authors:  I N Bruce; M Urowitz; R van Vollenhoven; C Aranow; J Fettiplace; M Oldham; B Wilson; C Molta; D Roth; D Gordon
Journal:  Lupus       Date:  2016-03-01       Impact factor: 2.911
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.